Senzime AB (publ) invites investors, financial analysts and media to a digital investor event on November 15, 2022, at 13:00-15:00 CET.
Pia Renaudin, CEO, will together with Kay Krüger (Business manager ExSpiron products) and Sorin J. Brull (Professor, board member of Senzime AB and the innovator of TetraGraph) cover company strategy, growth opportunities, new clinical guidelines, and long-term financial targets.
The presentations will be held in English, followed by a Q&A session. Attendees will be able to submit questions via the webcast.
Date and time Tuesday November 15, 2022, at 13:00-15:00 CET.
Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime’s employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.
Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world’s leading markets. The company’s shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at senzime.com.